Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects

Inclusion Criteria: 1. Healthy men and women (of nonchildbearing potential) between 20 and 60 years of age, inclusive. 2. Body mass index between 20.0 and 32.0 kg/m2, inclusive. 3. No clinically meaningful findings on physical examination, electrocardiogram, laboratory tests or vital signs 4. Subject has been given signed informed consent Exclusion Criteria: 1. History of any significant illness or disorder 2. Acute illness within 30 days of administration of first dose of study drug 3. Positive screening result for HIV, hepatitis B or hepatitis C 4. History of or current substance abuse (drug or alcohol) within past 1 year or positive test for drugs of abuse during screening 5. Use of nicotine-containing or vaping products within 3 months prior to screening or check-in 6. Use of cannabis within 45 days prior to check-in 7. Donation of blood within 3 months prior to screening, plasma within 2 weeks prior to screening or platelets within 6 weeks prior to screening 8. Participation in any other investigational study drug trial in which receipt of an investigational study drug occurred within past 30 days